SCHEMBL2964221

SCHEMBL2964221

CC#CCn1c(N2CCN(C(=O)OC(C)(C)C)CC2)nc(CO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)c1C(=N)SC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.36
CKS1B P61024 2/20 0.36
SKP1 P63208 2/20 0.36
SKP2 Q13309 2/20 0.36
ACHE P22303 2/20 0.35
ACKR3 P25106 2/20 0.34
KCNH2 Q12809 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
ESR2 Q92731 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
NR2F2 P24468 1/20 0.34
HTT P42858 1/20 0.34
PRMT5 O14744 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PKM P14618 1/20 0.33
GBA1 P04062 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961231 0.88 CKS1B (0.37) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL2964901 0.78 GBA1 (0.35) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL2965598 0.74 KCNH2 (0.40) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL2959239 0.74 ATM (0.40) CKS1BSKP1SKP2KCNH2SMN1; SMN2
SCHEMBL13201018 0.73 KCNH2 (0.40) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL13200917 0.71 KDM4E (0.42) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL13200916 0.71 ACHE (0.41) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL2962659 0.71 ALDH1A1 (0.42) CKS1BSKP1SKP2ACHEKCNH2
SCHEMBL2958599 0.70 KCNH2 (0.39) PTPN11CKS1BSKP1SKP2ACHE
SCHEMBL2957159 0.69 KCNH2 (0.40) PTPN11CKS1BSKP1SKP2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772226-B2 Condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-7772226-B2 Condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-10 US disclosed
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-01-15 US disclosed
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-01-15 US disclosed
US-20060100199-A1 Novel condensed imidazole derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-11 US disclosed
US-20060063787-A1 Condensed imidazole derivatives EISAI CO., LTD. (JP) 2006-03-23 US disclosed
EP-1514552-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE Eisai Co., Ltd. (JP) 2005-03-16 EP disclosed
US-20040116328-A1 Condensed imidazole derivatives EISAI CO., LTD. (JP) 2004-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100199-A1 Novel condensed imidazole derivatives H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 PTPN11 4324/4885CKS1B 144/4885SKP1 928/4885
US-20060063787-A1 Condensed imidazole derivatives DPP4, HDAC1, DPP7 PTPN11 2335/4885CKS1B 103/4885SKP1 1478/4885
US-20090018331-A1 CONDENSED IMIDAZOLE DERIVATIVES DPP4, HDAC1, DPP7 PTPN11 2335/4885CKS1B 103/4885SKP1 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.